Larotrectinib - Bayer/Loxo Oncology

Drug Profile

Larotrectinib - Bayer/Loxo Oncology

Alternative Names: ARRY 470; LOXO-101

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Loxo Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Solid tumours; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Solid tumours
  • Phase II Histiocytosis; Non-Hodgkin's lymphoma
  • Phase I/II CNS cancer
  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 01 Mar 2018 Loxo Oncology announces intention to submit MAA to EMA in 2018
  • 23 Feb 2018 Pooled safety and efficacy data from a phase I trial, phase I/II SCOUT trial and the phase II NAVIGATE in Solid tumours released by Loxo Oncology
  • 21 Dec 2017 Preregistration for Solid tumours (In adolescents, In children, In infants, Late-stage disease, Metastatic disease, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top